Please assess the completion status of the following clinical trial:

Trial Title: Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* NSCLC stage IIIA-IIIB~* Performance status 0 or 1 (Zubrod or WHO Scale)~Exclusion Criteria:~* Evidence of metastases either in a separate lobe of the lung, or extra thoracic~* Patients with high risk of radiation pneumonitis and or compromised lung function~* Estimated life expectancy of less than 3 months~* Prior chemotherapy for lung cancer~* Prior radiotherapy to the chest~* Prior surgery with curative intent for lung cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zalutumumab 8 mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).